KYOWA KIRIN CO., LTD.
- Country
- π―π΅Japan
- Ownership
- Public, Subsidiary
- Established
- 1949-07-01
- Employees
- 5.9K
- Market Cap
- -
- Website
- http://www.kyowa-kirin.co.jp
A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma
- Conditions
- Multiple Myeloma and Malignant Lymphoma
- Interventions
- Drug: KRN125(pegfilgrastim), PLR001(plerixafor)Drug: KRN8601(filgrastim), PLR001(plerixafor)
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT05007652
- Locations
- π―π΅
Kochi Health Sciences Center, Kochi, Japan
π―π΅National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan
π―π΅Niigata University Medical and Dental Hospital, Niigata, Japan
Long Term Follow-up Observational Study After Clinical Trials of AMG531 (Romiplostim) in Patients With Untreated Aplastic Anemia
- Conditions
- Aplastic Anemia
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT04870346
- Locations
- π―π΅
Kanazawa University, College of Medical Pharmaceutical and Health Sciences, School of Medicine, Department of Hematology, Kanazawa, Ishikawa Prefecture, Japan
Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLH
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04842019
- Locations
- π¨π³
Peking Union Medical College Hospital, Beijing, China
π¨π³Nanfang Hospital, Guangzhou, China
π¨π³The First Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China
Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLH
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT04842032
- Locations
- π¨π³
Shanghai 6th Hospital, Shanghai, China
π¨π³Guangzhou Women and Children Medical Center, Guangzhou, China
π¨π³Peking Union Medical College Hospital, Beijing, China
Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 213
- Registration Number
- NCT04771780
- Locations
- π―π΅
Medical Corporation Seijinkai Ikeda Hospital, Kanoya, Kagoshima, Japan
Clinical Study of KHK7791 in Hyperphosphatemia Patients on Peritoneal Dialysis
- First Posted Date
- 2021-02-23
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT04766385
- Locations
- π―π΅
Inoue Hospital, Suita, Osaka, Japan
Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
- First Posted Date
- 2021-02-23
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 169
- Registration Number
- NCT04766398
- Locations
- π―π΅
Inoue Hospital, Suita, Osaka, Japan
Clinical Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
- First Posted Date
- 2021-02-23
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 165
- Registration Number
- NCT04767581
- Locations
- π―π΅
Kikuchi medical clinic, Tsukuba, Ibaraki, Japan
A Phase 4 Study of Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque Psoriasis
- Conditions
- Moderate to Severe Plaque Psoriasis
- Interventions
- Drug: KHK4827-ActiveDrug: KHK4827-Placebo
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2021-09-30
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Registration Number
- NCT04614298
- Locations
- π¨π³
Site 07, Changchun, China
π¨π³Site 18, Xi'an, China
π¨π³Site 13, Changchun, China
A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration
- Conditions
- Healthy VolunteersWet Age-related Macular Degeneration
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 116
- Registration Number
- NCT04594681
- Locations
- π―π΅
Hakata clinic, Fukuoka, Japan